Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32001483.
- Also identified by DOI 10.1158/1078-0432.CCR-19-4060 and PMC identifier 7453631.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition.<i>See related article by Ryan et al., p. 1633</i>.
Medical subject headings
- Lung Neoplasms
- Proto-Oncogene Proteins p21(ras)